Carla Mendieta, APRN
Family · Fort Smith, ARNPI 1407522303
Payments from drug & device makers
Across 210 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$561
- AbbVie$544
- Novo Nordisk$402
- Bayer$333
- Pfizer$296
- Amgen$250
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,56999%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $561 |
| AbbVie | 34 | $544 |
| Novo Nordisk | 24 | $402 |
| Bayer | 20 | $333 |
| Pfizer | 18 | $296 |
| Amgen | 15 | $250 |
| Otsuka America Pharmaceutical, Inc. | 9 | $187 |
| Lilly USA, LLC | 11 | $164 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $148 |
| GSK | 8 | $116 |
| Exact Sciences | 6 | $102 |
| Axsome Therapeutics, Inc. | 5 | $82 |
| Antares Pharma, Inc. | 4 | $67 |
| Johnson & Johnson | 4 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $53 |
| Merck | 3 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Dexcom, Inc. | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Astellas Pharma US Inc | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
How this compares
$3,602 in reported general payments places this provider in the 85th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $91,863 |
| EliquisApixaban | 50 | $52,690 |
| JardianceEmpagliflozin | 22 | $32,193 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $27,812 |
| TradjentaLinagliptin | 12 | $15,488 |
| EntrestoSacubitril/Valsartan | 11 | $15,481 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $11,194 |
| LinzessLinaclotide | 12 | $8,458 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,089 |
| Arnuity ElliptaFluticasone Furoate | 23 | $5,338 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 192 | $5,332 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $5,046 |
| Gabapentin | 255 | $3,925 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $3,667 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $402 | $91,86358 claims |
| PfizerEliquis | $296 | $52,69050 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $116 | $44,34482 claims |
| NovartisEntresto | $15 | $15,48111 claims |
| AbbVieLinzess | $544 | $8,45812 claims |
| AstraZenecaBevespi Aerosphere, Symbicort | $561 | $8,33626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,103 family providers in Arkansas.
Other family in Fort Smith
- Nina CopelandFort Smith$207K
- Amanda DavisFort Smith$46K
- Scarlett BoneFort Smith$16K
- Nathan WilliamsonFort Smith$15K
- Yong OunpraseuthFort Smith$14K
- Karen WilliamsFort Smith$11K
- Nycole OliverFort Smith$10K
- Bentlee RundellFort Smith$10K
- Nata MatthewsFort Smith$10K
- Emily ChristensenFort Smith$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.